Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion type Assertion NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_head.
- NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion description "[Moreover, PRK1 activates AR even in the presence of the AR antagonist cyproterone acetate that is used in the clinical management of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_provenance.
- NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion evidence source_evidence_literature NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_provenance.
- NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion SIO_000772 12514133 NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_provenance.
- NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion wasDerivedFrom befree-20150227 NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_provenance.
- NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_assertion wasGeneratedBy ECO_0000203 NP643090.RASz_vH1agqolAw9ao0qd8gVtFPB6iEk09Lmo5Nx3fWeM130_provenance.